ProQR Therapeutics BV (PRQR) - Total Liabilities
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has total liabilities worth $54.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of ProQR Therapeutics BV's assets are long-term investments to see how much of total assets are deployed in long-term investments.
ProQR Therapeutics BV - Total Liabilities Trend (2012–2025)
This chart illustrates how ProQR Therapeutics BV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of ProQR Therapeutics BV.
ProQR Therapeutics BV Competitors by Total Liabilities
The table below lists competitors of ProQR Therapeutics BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Huaxin New Material Co Ltd Class A
SHE:300717
|
China | CN¥282.00 Million |
|
Humble Group AB
ST:HUMBLE
|
Sweden | Skr3.89 Billion |
|
HAXC Holdings (Beijing) Co. Ltd.
SHE:300928
|
China | CN¥144.77 Million |
|
Cosmo Chem
KO:005420
|
Korea | ₩584.05 Billion |
|
SC Asset Corporation Public Company Limited
BK:SC
|
Thailand | ฿44.31 Billion |
|
Beetaloo Energy Australia Limited
AU:BTL
|
Australia | AU$40.05 Million |
|
Batavia Prosperindo Int
JK:BPII
|
Indonesia | Rp3.40 Trillion |
|
Fiera Capital Corporation
TO:FSZ
|
Canada | CA$956.48 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down ProQR Therapeutics BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PRQR net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProQR Therapeutics BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProQR Therapeutics BV (2012–2025)
The table below shows the annual total liabilities of ProQR Therapeutics BV from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $74.44 Million | -9.46% |
| 2024-12-31 | $82.22 Million | -22.87% |
| 2023-12-31 | $106.59 Million | -4.55% |
| 2022-12-31 | $111.68 Million | +1.92% |
| 2021-12-31 | $109.57 Million | +112.29% |
| 2020-12-31 | $51.61 Million | +93.99% |
| 2019-12-31 | $26.61 Million | +51.63% |
| 2018-12-31 | $17.55 Million | +6.05% |
| 2017-12-31 | $16.54 Million | +26.43% |
| 2016-12-31 | $13.09 Million | +16.84% |
| 2015-12-31 | $11.20 Million | +58.41% |
| 2014-12-31 | $7.07 Million | +11.71% |
| 2013-12-31 | $6.33 Million | +1908.56% |
| 2012-12-31 | $315.10K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more